Con: should asymptomatic patients with moderate-to-severe ?OSA be treated? Source: Breathe, 15 (1) 11; 10.1183/20734735.0347-2018 Year: 2019
Treatment of non-sleepy OSA patients - what are the alternatives ? Source: Annual Congress 2010 - Practical Workshop: "Treatment of non-sleepy OSA patients" Year: 2010
When to treat elderly OSA patients Source: ERS Conference Year: 2015
Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015
Mild OSAS: Is CPAP therapy actually required for these patients? Source: International Congress 2018 – From continuous positive airway pressure (CPAP) and adherence to CPAP to asthma-COPD overlap syndrome (ACOS) Year: 2018
Auto-CPAP for treatment of OSAS in severe obese patients Source: Eur Respir J 2005; 26: Suppl. 49, 723s Year: 2005
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018
Patients at risk for COPD compared to patients diagnosed with COPD Source: Annual Congress 2009 - Epidemiology of COPD Year: 2009
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019
Compliance for NIMV treatment in moderate and severe OSAS patients Source: Annual Congress 2012 - Clinical predictors of OSA, adherence to CPAP and psychology Year: 2012
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004
Evaluation of pain pressure threshold in patients with moderate to severe symptomatic COPD and healthy controls Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020
Treating OSAS in children Source: International Congress 2017 – ME1 Treating obstructive sleep apnoea syndrome in children Year: 2017
Differences between patients with overlap syndrome (COPD + OSAS) and patients with OSAS Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults I: questionnaires, epidemiology and sleep studies Year: 2015
Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment Source: Breathe, 17 (2) 210024; 10.1183/20734735.0024-2021 Year: 2021
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Phenotyping acute exacerbation of COPD: what more can we do for hospitalised patients? Source: ERJ Open Res, 7 (3) 00362-2021; 10.1183/23120541.00362-2021 Year: 2021
Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021
The severity of anxiety in COPD patients (pts) Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016